New antihypertensive drugs

Here are some new antihypertensive drugs that have been approved or are in development:

  1. Finerenone (Kerendia): Approved in 2020, finerenone is a non-steroidal mineralocorticoid receptor antagonist that is used to treat patients with chronic kidney disease (CKD) and type 2 diabetes.
  2. Luseogliflozin (VestKEN): Approved in 2020, luseogliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that is used to treat patients with type 2 diabetes and hypertension.
  3. Aliskiren (Tekturna): Approved in 2007, aliskiren is a direct renin inhibitor that is used to treat patients with hypertension. It is often used in combination with other antihypertensive medications.
  4. Sacubitril (Entresto): Approved in 2015, sacubitril is a neprilysin inhibitor that is used to treat patients with heart failure and hypertension.
  5. Valsartan (Diovan): Approved in 1996, valsartan is an angiotensin II receptor antagonist that is used to treat patients with hypertension and heart failure.
  6. Telmisartan (Micardis): Approved in 1998, telmisartan is an angiotensin II receptor antagonist that is used to treat patients with hypertension and heart failure.
  7. Candesartan (Atacand): Approved in 1997, candesartan is an angiotensin II receptor antagonist that is used to treat patients with hypertension and heart failure.
  8. Eprosartan (Teveten): Approved in 1997, eprosartan is an angiotensin II receptor antagonist that is used to treat patients with hypertension.
  9. Olmesartan (Benicar): Approved in 2002, olmesartan is an angiotensin II receptor antagonist that is used to treat patients with hypertension.
  10. Losartan (Cozaar): Approved in 1995, losartan is an angiotensin II receptor antagonist that is used to treat patients with hypertension and heart failure.

New antihypertensive drugs in development:

  1. Rapastinel (GLYX-13): A glutamate receptor agonist that is being developed to treat patients with hypertension and heart failure.
  2. BAY 94-8862: A novel angiotensin receptor antagonist that is being developed to treat patients with hypertension and heart failure.
  3. AZD1236: A novel angiotensin receptor antagonist that is being developed to treat patients with hypertension and heart failure.
  4. LCL161: A novel SGLT2 inhibitor that is being developed to treat patients with type 2 diabetes and hypertension.
  5. BAY 85-3934: A novel SGLT2 inhibitor that is being developed to treat patients with type 2 diabetes and hypertension.

Note: This is not an exhaustive list, and new antihypertensive drugs are being developed and approved regularly.